カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の後腹膜線維症治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Drugs for Retroperitoneal Fibrosis Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19276）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19276
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：106
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の後腹膜線維症治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

後腹膜線維症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の後腹膜線維症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

後腹膜線維症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・コルチコステロイド、免疫抑制剤

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他

世界の後腹膜線維症治療薬市場の主要な市場プレーヤーは以下のとおりです。
・AstraZeneca Pharmaceuticals、Eli Lilly、GlaxoSmithKline、Abbott、Johnson & Johnson、Sanofi、Pfizer、Merck、Bayer、Novartis

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、後腹膜線維症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な後腹膜線維症治療薬メーカーの企業概要、2019年～2022年までの後腹膜線維症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な後腹膜線維症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別後腹膜線維症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの後腹膜線維症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での後腹膜線維症治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および後腹膜線維症治療薬の産業チェーンを掲載しています。
・第13、14、15章では、後腹膜線維症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 後腹膜線維症治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：コルチコステロイド、免疫抑制剤
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他
- 世界の後腹膜線維症治療薬市場規模・予測
- 世界の後腹膜線維症治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- AstraZeneca Pharmaceuticals、Eli Lilly、GlaxoSmithKline、Abbott、Johnson & Johnson、Sanofi、Pfizer、Merck、Bayer、Novartis
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：コルチコステロイド、免疫抑制剤
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他
・後腹膜線維症治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・後腹膜線維症治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・後腹膜線維症治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・後腹膜線維症治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・後腹膜線維症治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Drugs for Retroperitoneal Fibrosis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Drugs for Retroperitoneal Fibrosis market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacy accounting for % of the Drugs for Retroperitoneal Fibrosis global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Corticosteroids segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Drugs for Retroperitoneal Fibrosis include AstraZeneca Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Abbott, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drugs for Retroperitoneal Fibrosis market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Corticosteroids
Immunosuppressant
Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other
The key market players for global Drugs for Retroperitoneal Fibrosis market are listed below:
AstraZeneca Pharmaceuticals
Eli Lilly
GlaxoSmithKline
Abbott
Johnson & Johnson
Sanofi
Pfizer
Merck
Bayer
Novartis
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Retroperitoneal Fibrosis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Retroperitoneal Fibrosis, with price, sales, revenue and global market share of Drugs for Retroperitoneal Fibrosis from 2019 to 2022.
Chapter 3, the Drugs for Retroperitoneal Fibrosis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Retroperitoneal Fibrosis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Drugs for Retroperitoneal Fibrosis market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Retroperitoneal Fibrosis.
Chapter 13, 14, and 15, to describe Drugs for Retroperitoneal Fibrosis sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Drugs for Retroperitoneal Fibrosis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Retroperitoneal Fibrosis Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Corticosteroids
1.2.3 Immunosuppressant
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Retroperitoneal Fibrosis Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Other
1.4 Global Drugs for Retroperitoneal Fibrosis Market Size & Forecast
1.4.1 Global Drugs for Retroperitoneal Fibrosis Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Drugs for Retroperitoneal Fibrosis Sales in Volume (2017-2028)
1.4.3 Global Drugs for Retroperitoneal Fibrosis Price (2017-2028)
1.5 Global Drugs for Retroperitoneal Fibrosis Production Capacity Analysis
1.5.1 Global Drugs for Retroperitoneal Fibrosis Total Production Capacity (2017-2028)
1.5.2 Global Drugs for Retroperitoneal Fibrosis Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Retroperitoneal Fibrosis Market Drivers
1.6.2 Drugs for Retroperitoneal Fibrosis Market Restraints
1.6.3 Drugs for Retroperitoneal Fibrosis Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca Pharmaceuticals
2.1.1 AstraZeneca Pharmaceuticals Details
2.1.2 AstraZeneca Pharmaceuticals Major Business
2.1.3 AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Product and Services
2.1.4 AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Drugs for Retroperitoneal Fibrosis Product and Services
2.2.4 Eli Lilly Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Product and Services
2.3.4 GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Drugs for Retroperitoneal Fibrosis Product and Services
2.4.4 Abbott Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Drugs for Retroperitoneal Fibrosis Product and Services
2.5.4 Johnson & Johnson Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Drugs for Retroperitoneal Fibrosis Product and Services
2.6.4 Sanofi Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Drugs for Retroperitoneal Fibrosis Product and Services
2.7.4 Pfizer Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Drugs for Retroperitoneal Fibrosis Product and Services
2.8.4 Merck Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Bayer
2.9.1 Bayer Details
2.9.2 Bayer Major Business
2.9.3 Bayer Drugs for Retroperitoneal Fibrosis Product and Services
2.9.4 Bayer Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Drugs for Retroperitoneal Fibrosis Product and Services
2.10.4 Novartis Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Drugs for Retroperitoneal Fibrosis Breakdown Data by Manufacturer
3.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Drugs for Retroperitoneal Fibrosis
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Retroperitoneal Fibrosis Manufacturer Market Share in 2021
3.4.2 Top 6 Drugs for Retroperitoneal Fibrosis Manufacturer Market Share in 2021
3.5 Global Drugs for Retroperitoneal Fibrosis Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Drugs for Retroperitoneal Fibrosis Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drugs for Retroperitoneal Fibrosis Market Size by Region
4.1.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Region (2017-2028)
4.1.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2028)
4.2 North America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.3 Europe Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.4 Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.5 South America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.6 Middle East and Africa Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Type (2017-2028)
5.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Type (2017-2028)
5.3 Global Drugs for Retroperitoneal Fibrosis Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Application (2017-2028)
6.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Application (2017-2028)
6.3 Global Drugs for Retroperitoneal Fibrosis Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
7.2 North America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
7.3 North America Drugs for Retroperitoneal Fibrosis Market Size by Country
7.3.1 North America Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
7.3.2 North America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
8.2 Europe Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
8.3 Europe Drugs for Retroperitoneal Fibrosis Market Size by Country
8.3.1 Europe Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
8.3.2 Europe Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
9.2 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
9.3 Asia-Pacific Drugs for Retroperitoneal Fibrosis Market Size by Region
9.3.1 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
10.2 South America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
10.3 South America Drugs for Retroperitoneal Fibrosis Market Size by Country
10.3.1 South America Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
10.3.2 South America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
11.2 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
11.3 Middle East & Africa Drugs for Retroperitoneal Fibrosis Market Size by Country
11.3.1 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Drugs for Retroperitoneal Fibrosis and Key Manufacturers
12.2 Manufacturing Costs Percentage of Drugs for Retroperitoneal Fibrosis
12.3 Drugs for Retroperitoneal Fibrosis Production Process
12.4 Drugs for Retroperitoneal Fibrosis Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Drugs for Retroperitoneal Fibrosis Typical Distributors
13.3 Drugs for Retroperitoneal Fibrosis Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Drugs for Retroperitoneal Fibrosis Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Drugs for Retroperitoneal Fibrosis Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. AstraZeneca Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Pharmaceuticals Major Business
Table 5. AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Product and Services
Table 6. AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 8. Eli Lilly Major Business
Table 9. Eli Lilly Drugs for Retroperitoneal Fibrosis Product and Services
Table 10. Eli Lilly Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Major Business
Table 13. GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Product and Services
Table 14. GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Abbott Basic Information, Manufacturing Base and Competitors
Table 16. Abbott Major Business
Table 17. Abbott Drugs for Retroperitoneal Fibrosis Product and Services
Table 18. Abbott Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 20. Johnson & Johnson Major Business
Table 21. Johnson & Johnson Drugs for Retroperitoneal Fibrosis Product and Services
Table 22. Johnson & Johnson Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Sanofi Basic Information, Manufacturing Base and Competitors
Table 24. Sanofi Major Business
Table 25. Sanofi Drugs for Retroperitoneal Fibrosis Product and Services
Table 26. Sanofi Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Drugs for Retroperitoneal Fibrosis Product and Services
Table 30. Pfizer Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Merck Basic Information, Manufacturing Base and Competitors
Table 32. Merck Major Business
Table 33. Merck Drugs for Retroperitoneal Fibrosis Product and Services
Table 34. Merck Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Bayer Basic Information, Manufacturing Base and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Drugs for Retroperitoneal Fibrosis Product and Services
Table 38. Bayer Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Drugs for Retroperitoneal Fibrosis Product and Services
Table 42. Novartis Drugs for Retroperitoneal Fibrosis Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Drugs for Retroperitoneal Fibrosis Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global Drugs for Retroperitoneal Fibrosis Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Drugs for Retroperitoneal Fibrosis, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Drugs for Retroperitoneal Fibrosis Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Drugs for Retroperitoneal Fibrosis Production Site of Key Manufacturer
Table 48. Drugs for Retroperitoneal Fibrosis New Entrant and Capacity Expansion Plans
Table 49. Drugs for Retroperitoneal Fibrosis Mergers & Acquisitions in the Past Five Years
Table 50. Global Drugs for Retroperitoneal Fibrosis Sales by Region (2017-2022) & (K Units)
Table 51. Global Drugs for Retroperitoneal Fibrosis Sales by Region (2023-2028) & (K Units)
Table 52. Global Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Drugs for Retroperitoneal Fibrosis Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 55. Global Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 56. Global Drugs for Retroperitoneal Fibrosis Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Drugs for Retroperitoneal Fibrosis Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Drugs for Retroperitoneal Fibrosis Price by Type (2017-2022) & (US$/Unit)
Table 59. Global Drugs for Retroperitoneal Fibrosis Price by Type (2023-2028) & (US$/Unit)
Table 60. Global Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 61. Global Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 62. Global Drugs for Retroperitoneal Fibrosis Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Drugs for Retroperitoneal Fibrosis Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Drugs for Retroperitoneal Fibrosis Price by Application (2017-2022) & (US$/Unit)
Table 65. Global Drugs for Retroperitoneal Fibrosis Price by Application (2023-2028) & (US$/Unit)
Table 66. North America Drugs for Retroperitoneal Fibrosis Sales by Country (2017-2022) & (K Units)
Table 67. North America Drugs for Retroperitoneal Fibrosis Sales by Country (2023-2028) & (K Units)
Table 68. North America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Drugs for Retroperitoneal Fibrosis Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 71. North America Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 72. North America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 73. North America Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 74. Europe Drugs for Retroperitoneal Fibrosis Sales by Country (2017-2022) & (K Units)
Table 75. Europe Drugs for Retroperitoneal Fibrosis Sales by Country (2023-2028) & (K Units)
Table 76. Europe Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Drugs for Retroperitoneal Fibrosis Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 79. Europe Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 80. Europe Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 81. Europe Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 90. South America Drugs for Retroperitoneal Fibrosis Sales by Country (2017-2022) & (K Units)
Table 91. South America Drugs for Retroperitoneal Fibrosis Sales by Country (2023-2028) & (K Units)
Table 92. South America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Drugs for Retroperitoneal Fibrosis Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 95. South America Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 96. South America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 97. South America Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Application (2023-2028) & (K Units)
Table 106. Drugs for Retroperitoneal Fibrosis Raw Material
Table 107. Key Manufacturers of Drugs for Retroperitoneal Fibrosis Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Drugs for Retroperitoneal Fibrosis Typical Distributors
Table 111. Drugs for Retroperitoneal Fibrosis Typical Customers
List of Figures
Figure 1. Drugs for Retroperitoneal Fibrosis Picture
Figure 2. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Type in 2021
Figure 3. Corticosteroids
Figure 4. Immunosuppressant
Figure 5. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Application in 2021
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Pharmacy
Figure 9. Other
Figure 10. Global Drugs for Retroperitoneal Fibrosis Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Drugs for Retroperitoneal Fibrosis Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Drugs for Retroperitoneal Fibrosis Sales (2017-2028) & (K Units)
Figure 13. Global Drugs for Retroperitoneal Fibrosis Price (2017-2028) & (US$/Unit)
Figure 14. Global Drugs for Retroperitoneal Fibrosis Production Capacity (2017-2028) & (K Units)
Figure 15. Global Drugs for Retroperitoneal Fibrosis Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Drugs for Retroperitoneal Fibrosis Market Drivers
Figure 17. Drugs for Retroperitoneal Fibrosis Market Restraints
Figure 18. Drugs for Retroperitoneal Fibrosis Market Trends
Figure 19. Global Drugs for Retroperitoneal Fibrosis Sales Market Share by Manufacturer in 2021
Figure 20. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Manufacturer in 2021
Figure 21. Drugs for Retroperitoneal Fibrosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Drugs for Retroperitoneal Fibrosis Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Drugs for Retroperitoneal Fibrosis Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Drugs for Retroperitoneal Fibrosis Sales Market Share by Region (2017-2028)
Figure 25. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Region (2017-2028)
Figure 26. North America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028) & (USD Million)
Figure 27. Europe Drugs for Retroperitoneal Fibrosis Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue (2017-2028) & (USD Million)
Figure 29. South America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue (2017-2028) & (USD Million)
Figure 31. Global Drugs for Retroperitoneal Fibrosis Sales Market Share by Type (2017-2028)
Figure 32. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Type (2017-2028)
Figure 33. Global Drugs for Retroperitoneal Fibrosis Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 35. Global Drugs for Retroperitoneal Fibrosis Revenue Market Share by Application (2017-2028)
Figure 36. Global Drugs for Retroperitoneal Fibrosis Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Drugs for Retroperitoneal Fibrosis Sales Market Share by Type (2017-2028)
Figure 38. North America Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 39. North America Drugs for Retroperitoneal Fibrosis Sales Market Share by Country (2017-2028)
Figure 40. North America Drugs for Retroperitoneal Fibrosis Revenue Market Share by Country (2017-2028)
Figure 41. United States Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Drugs for Retroperitoneal Fibrosis Sales Market Share by Type (2017-2028)
Figure 45. Europe Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 46. Europe Drugs for Retroperitoneal Fibrosis Sales Market Share by Country (2017-2028)
Figure 47. Europe Drugs for Retroperitoneal Fibrosis Revenue Market Share by Country (2017-2028)
Figure 48. Germany Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue Market Share by Region (2017-2028)
Figure 57. China Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Drugs for Retroperitoneal Fibrosis Sales Market Share by Type (2017-2028)
Figure 64. South America Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 65. South America Drugs for Retroperitoneal Fibrosis Sales Market Share by Country (2017-2028)
Figure 66. South America Drugs for Retroperitoneal Fibrosis Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Drugs for Retroperitoneal Fibrosis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Drugs for Retroperitoneal Fibrosis in 2021
Figure 78. Manufacturing Process Analysis of Drugs for Retroperitoneal Fibrosis
Figure 79. Drugs for Retroperitoneal Fibrosis Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の嚢胞性線維症（CF）用粘液除去機器市場2022年：市場規模予測（～2028年）
  • ヒト嚢胞性線維症膜貫通コンダクタンス制御因子（CFTR）キットのグローバル市場展望 2023年-2029年：CFTR CLIAキット、CFTR ELISAキット、その他
  • 世界のオシメルチニブ医薬品市場2022年：市場規模予測（～2028年）
  • 世界のエクセナチド薬物市場2022年：市場規模予測（～2028年）
  • 世界のペガスパルガーゼ薬物市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19276 )"世界の後腹膜線維症治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Drugs for Retroperitoneal Fibrosis Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。